Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Fabrazyme - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Fabrazyme

Approved

STANDARD

Fabrazyme

-🇵🇭 Food and Drug Administration - Philippines

Approval Date: Feb 1, 2026
Approval ID: 89bf03e0df967a61
Company: -
Type: Standard

Approval Details

Approval Id: 89bf03e0df967a61
Drug Approval Philippines Name: Fabrazyme
Product Name: Fabrazyme
Registration Number: BR-1048
Brand Name: Fabrazyme
Generic Name: Agalsidase Beta
Dosage Form: Powder for Concentrate for Solution for Infusion (IV)
Dosage Strength: 35 mg
Manufacturer: -
Issuance Date: N/A
Expiry Date: Sanofi-Aventis Philippines, Inc.
Pharmacologic Category: 20 mL Type I glass vial with gray chlorobutyl stopper and aluminum crimp seal (Box of 1's)
Classification: Prescription Drug (RX)

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Feb 1, 2026

Approval ID

89bf03e0df967a61

Type

Standard

Back to Philippines FDA Approvals